Medicinal Cannabis Applications Target the Development of Enhanced Therapies and Treatments for Various Health Disorders

Tuesday, March 21, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

PALM BEACH, Florida, March 21, 2017 /PRNewswire/ -- News Commentary 


studies concerning the therapeutic attributes of Cannabidiol (CBD) have pointed to growing evidence to suggest that it could help in the treatment of anxiety-related and other health disorders. With recent research and development aimed at identifying
new therapies and treatments for various ailments, companies are focusing on improving therapies such as: India Globalization Capital, Inc. (NYSE:IGC), INSYS Therapeutics, Inc. (NASDAQ:INSY), Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), Terra Tech Corp. (OTC:TRTC) and Cannabics Pharmaceuticals Inc. (OTC:CNBX).

India Globalization Capital, Inc. (NYSE-MKT:IGC) today announces its provisional patent filing (IGC-506) for the treatment of multiple types of eating disorders by a method and combination of cannabis extracts and other compounds. IGC-506 is being developed for both human and veterinary use, should this filing progress to the issuance of a patent. Read this and more news for IGC at:

"The development of cannabis-based combination therapies represents a large, unique opportunity, and we believe we are the first mover in this emerging specialty-pharmaceutical sector. Over the past three years, we have built a strong IP portfolio and now propose to obtain funding to commence pre-clinical and clinical trials as appropriate. Securing FDA approval for combination therapies is generally much faster and less expensive than the process for new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner," states Ram Mukunda, chief executive officer of IGC. 

As previously reported ( ), IGC has started a review of international medical facilities to commence preclinical and clinical trials in support of the company's patent portfolio, which includes IGC-501 for neuropathic pain; IGC-502 for the treatment of seizures; and IGC-504 for eating disorders, including cachexia. Read more about the patent details at:

In other medicinal companies in the medical marijuana/cannabidiol arena and market performances include:  

INSYS Therapeutics, Inc. (NASDAQ:INSY) closed up on Monday at $10.26 trading over 500,000 thousand shares by the market close. Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) closed up on Monday and was up slightly in after market trading closing at $19.62. Zynerba Pharmaceuticals last week announced that it has completed enrollment in the Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in adult epilepsy patients with refractory focal seizures. The company also announced that enrollment has completed in the Phase 2 STOP (Synthetic Transdermal Cannabidiol for the Treatment of Knee Pain due to Osteoarthritis) clinical trial evaluating ZYN002 CBD gel for the treatment of osteoarthritis.

Terra Tech Corp. (OTCQX:TRTC) closed up over 5% on Monday at $0.287 trading over 2.7 million shares by the market close. Terra Tech is in the final stages of designing a state-of-the-art cultivation facility projected to produce over one metric ton of premium grade cannabis per annum for its IVXX brand.

Cannabics Pharmaceuticals Inc. (OTCQB:CNBX) closed up over 12% on Monday at $2.7199 trading over 500,000 shares by the market close. Cannabics Pharmaceuticals is dedicated to the development of personalized anti-cancer and palliative treatments. The company's R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. Cannabics Pharmaceutical's focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.

DISCLAIMER: (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated three thousand nine hundred dollars for news coverage of the current press release issued by India Globalization Capital, Inc. by the company. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.

Contact Information: +1(561)325-8757



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store